Scholarlink

<p>A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm (MDS) in Asia patients is lacking. Diagnostic clinicopathologic features, cytogenetic changes, and gene mutations of ethnic Asian patients with primary MDS were analyzed. Variables were evaluated for associations with overall survival (OS), leukemia-free survival (LFS), and time to progression to secondary AML (TTP-sAML). Prognostic scores were built as a weighted sum of prognostic variables for each patient. The cohort comprised 1225 patients, with at least one gene mutation identified in 1177 patients (96%). Genomic factors associated with inferior outcomes included monosomy 7, del(5q), and <i>GNAS</i> and <i>TP53</i> mutations for OS; trisomy 19, del(5q), monosomy 7, and <i>GNAS</i>, <i>PTPN11</i> and <i>TP53</i> mutations for LFS; and i(17q), del(5q), and <i>NPM1</i>, <i>NRAS</i>, <i>GNAS</i>, <i>IDH2</i>, <i>SF3B1</i> and <i>RUNX1</i> mutations for TTP-sAML. The Asian Prognostic Scoring System (APSS) was determined, stratifying patients into six prognostic risk categories. The APSS, compared with the International Prognostic Scoring System molecular (IPSS-M), showed superior concordance indices (C-indices) for OS (0.73 <i>versus</i> 0.57), LFS (0.72 <i>versus</i> 0.59), and TTP-sAML (0.75 <i>versus</i> 0.65) for this Asian cohort. In conclusion, the APSS enhanced prognostication of primary MDS in Asia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Harinder Gill,
  • Rita Yim,
  • Paul Lee,
  • Xavier Cheng-Hong Tsai,
  • Vivian W. K. Li,
  • Garret M. K. Leung,
  • Melissa Ooi,
  • Tsz-Shing Hui,
  • Radha Raghupathy,
  • Lynn Chin,
  • Lester Au,
  • Qi Zhang,
  • Tony K. Y. Wu,
  • Carmen Y. Y. Lee,
  • Wee-Joo Chng,
  • Hwei-Fang Tien,
  • Hsin-An Hou,
  • Yok-Lam Kwong

摘要

A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm (MDS) in Asia patients is lacking. Diagnostic clinicopathologic features, cytogenetic changes, and gene mutations of ethnic Asian patients with primary MDS were analyzed. Variables were evaluated for associations with overall survival (OS), leukemia-free survival (LFS), and time to progression to secondary AML (TTP-sAML). Prognostic scores were built as a weighted sum of prognostic variables for each patient. The cohort comprised 1225 patients, with at least one gene mutation identified in 1177 patients (96%). Genomic factors associated with inferior outcomes included monosomy 7, del(5q), and GNAS and TP53 mutations for OS; trisomy 19, del(5q), monosomy 7, and GNAS, PTPN11 and TP53 mutations for LFS; and i(17q), del(5q), and NPM1, NRAS, GNAS, IDH2, SF3B1 and RUNX1 mutations for TTP-sAML. The Asian Prognostic Scoring System (APSS) was determined, stratifying patients into six prognostic risk categories. The APSS, compared with the International Prognostic Scoring System molecular (IPSS-M), showed superior concordance indices (C-indices) for OS (0.73 versus 0.57), LFS (0.72 versus 0.59), and TTP-sAML (0.75 versus 0.65) for this Asian cohort. In conclusion, the APSS enhanced prognostication of primary MDS in Asia.